Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5979
    -0.0026 (-0.44%)
     
  • NZD/EUR

    0.5530
    -0.0013 (-0.23%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    82.38
    +1.03 (+1.27%)
     
  • GOLD

    2,227.50
    +14.80 (+0.67%)
     
  • NASDAQ

    18,264.95
    -15.89 (-0.09%)
     
  • FTSE

    7,960.43
    +28.45 (+0.36%)
     
  • Dow Jones

    39,766.20
    +6.12 (+0.02%)
     
  • DAX

    18,494.46
    +17.37 (+0.09%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.4040
    -0.3760 (-0.41%)
     

DICE Therapeutics to Participate at Upcoming Investor Conferences

DICE Therapeutics, Inc.
DICE Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will participate at the following investor conferences:

  • SVB Securities Global Biopharma Conference 2023 
    Fireside Chat: Tuesday, February 14 at 2:20 p.m. ET

  • 43rd Annual Cowen Healthcare Conference 
    Dermatology Panel: Tuesday, March 7 at 12:50 p.m. ET

Live and archived webcasts of the presentations will be accessible under “News & Events” in the Investors section of the company's website for 90 days after the applicable event.

ADVERTISEMENT

About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Contacts:

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
investors@dicetx.com